Ge Long Hui·2025-08-28 10:33Group 1: Financial Performance - The company reported a total revenue increase of approximately $751.8 million or about 44.7% to approximately $2,432.6 million for the six months ending June 30, 2025 [1] - Product revenue increased by approximately $742.5 million or about 44.5% to approximately $2,410.6 million during the same period [1] - The net profit for the period was approximately $95.6 million, a significant recovery from a net loss of approximately $371.6 million for the six months ending June 30, 2024 [1] Group 2: Research and Development Expenses - Research and development expenses increased by $91.7 million (or 10.0%) from $915.1 million in the previous year to $1,006.8 million for the six months ending June 30, 2025 [1] - Internal R&D expenses grew by $21.5 million (or 3.7%) to $606.5 million, primarily due to the expansion of global R&D facilities and an increase in clinical and preclinical candidates [1] Group 3: Gross Profit and Margin - Gross profit from product sales increased to $2,081.0 million, up from $1,405.0 million in the same period last year, driven by the increase in product revenue [2] - The gross margin improved from 84.2% in the previous year to 86.3% for the six months ending June 30, 2025, attributed to a higher sales proportion of Baiyueze compared to other products [2] Group 4: Sales Performance of Baiyueze - Global sales of Baiyueze reached $1,741.5 million, a growth of 54.7% compared to the same period last year [3] - U.S. sales of Baiyueze totaled $1,246.9 million, a 50.1% increase from $830.8 million, driven by robust demand across all indications and moderate net pricing benefits [3] - European sales of Baiyueze amounted to $266.4 million, a year-on-year increase of 79.7%, benefiting from market share growth in major European markets [3]